ImmuCell Corp

ImmuCell Corp has a market capitalization of $76.63 million and a price-to-book ratio of 2.83, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by $3.81 million in cash and equivalents, but its long-term debt of $9.10 million suggests a moderate leverage profile. The current ratio of 4.26 indicates strong short-term liquidity, with current assets significantly outpacing current liabilities.

Profitability metrics reveal a challenging operating environment for ImmuCell. The company reported a net loss of $1.04 million and an operating loss of $591,210 in the latest period, resulting in a negative return on equity of -3.84% and a return on assets of -2.45%. These figures fall below the industry median for profitability metrics, suggesting operational inefficiencies or competitive pressures.

Geographically, ImmuCell's revenue is concentrated in the United States, with no material international operations disclosed. The company's product portfolio is centered on veterinary diagnostics and therapeutics, with limited diversification into human health applications. This concentration increases exposure to domestic regulatory and market shifts.

Looking ahead, ImmuCell's revenue is projected to grow by 8.1% year-over-year, driven by expansion in its veterinary product lines and potential new product launches. However, the company's operating cash flow of $2.48 million and free cash flow of $439,130 indicate limited capacity for reinvestment or debt reduction without external financing.

The risk assessment highlights moderate liquidity risk due to the company's negative net cash position after accounting for total debt. While dilution risk is currently low, the company's capital structure includes $9.10 million in long-term debt, which could necessitate future equity or debt financing. Adjustments in the valuation model reflect the company's negative earnings and limited cash flow generation.

Recent filings and transcripts indicate ongoing R&D efforts in immuno-enhancing therapies and a focus on expanding the company's veterinary diagnostic product line. The company has not disclosed any material legal or regulatory issues in the latest 10-K filing, but its reliance on a narrow product base remains a strategic risk.